Prostate Cancer Market: Innovation Driving New Frontiers in Care
The prostate cancer market is forecast to grow from $10.7bn in 2022 to a peak of $25.1bn in 2029, driven by next-generation hormonal therapies, PARP inhibitor combinations, and radioligand therapies. However, the market will face a downturn post-2029 as key brands lose exclusivity, with generics expected to account for 57% of total revenue by 2032.
Xtandi and Zytiga continue to dominate the market, but their upcoming patent expiries will reshape the treatment landscape. Meanwhile, Pluvicto, the first PSMA-targeted radiotherapy, is gaining traction in mCRPC and is expected to expand into earlier lines of therapy. PARP inhibitors such as Lynparza, Talzenna, and Zejula are increasingly used in biomarker-defined mCRPC populations, though label restrictions and testing rates remain barriers to broader uptake.
The recurrent/progressive setting is projected to see the most significant growth, rising from 1.4% of total sales in 2022 to 24% by 2032, driven by label expansions for agents like Xtandi and Nubeqa. Despite setbacks in immunotherapy, the pipeline remains active, with over 300 assets in development, including gene therapies, bispecific T-cell engagers, and ADC candidates.
In this report we cover:
- Key growth drivers: Next-generation ARPIs, radioligand therapies, and biomarker-driven treatment strategies across the US, EU5, and Japan.
- Promising therapies: Xtandi, Zytiga, Pluvicto, Lynparza + abiraterone, Talzenna + Xtandi, and Nubeqa in earlier-stage disease.
- Novel modalities: PSMA-targeted radiotherapies (Pluvicto, PNT2002), PARP inhibitors, and emerging ADCs and bispecifics.
